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Phase 2 Randomised Controlled 
Trial and Feasibility Study of Future 
Care Planning in Patients with 
Advanced Heart Disease
Martin A. Denvir1, Sarah Cudmore1, Gill Highet2, Shirley Robertson1, Lisa Donald1, 
Jacqueline Stephen3, Kristin Haga1, Karen Hogg4, Christopher J. Weir5, Scott A. Murray2 & 
Kirsty Boyd2
Future Care Planning (FCP) rarely occurs in patients with heart disease until close to death by which 
time the potential benefits are lost. We assessed the feasibility, acceptability and tested a design of 
a randomised trial evaluating the impact of FCP in patients and carers. 50 patients hospitalised with 
acute heart failure or acute coronary syndrome and with predicted 12 month mortality risk of >20% 
were randomly allocated to FCP or usual care for 12 weeks upon discharge and then crossed-over for 
the next 12 weeks. Quality of life, symptoms and anxiety/distress were assessed by questionnaire. 
Hospitalisation and mortality events were documented for 6 months post-discharge. FCP increased 
implementation and documentation of key decisions linked to end-of-life care. FCP did not increase 
anxiety/distress (Kessler score -E 16.7 (7.0) vs D 16.8 (7.3), p = 0.94). Quality of life was unchanged 
(EQ5D: E 0.54(0.29) vs D 0.56(0.24), p = 0.86) while unadjusted hospitalised nights was lower  
(E 8.6 (15.3) vs D 11.8 (17.1), p = 0.01). Qualitative interviews indicated that FCP was highly valued by 
patients, carers and family physicians. FCP is feasible in a randomised clinical trial in patients with acute 
high risk cardiac conditions. A Phase 3 trial is needed urgently.
A holistic palliative care approach is now recommended in international guidelines as a key component of care for 
patients with advanced chronic heart failure1–3. However, numerous reports internationally suggest inadequate 
delivery of such care4–6. Barriers include a lack of randomised trials, a deeply engrained culture of curative care 
among cardiologists and the challenges of spending longer talking with patients and their families about their 
future care needs and goals.
Palliative care interventions have been shown to improve outcomes in cancer with one trial suggesting a 
mortality benefit7 and several others showing improvements in symptoms and quality of life (QoL)8–10. In heart 
failure, small studies have demonstrated improvements in breathlessness using opioids11 and oxygen12. Trials 
of palliative care for advanced illness, including heart failure among others, have shown mixed results with one 
showing no impact on symptoms or QoL13, and another showing clear improvements in QoL and resource uti-
lisation14. Trials focusing on heart failure have also shown improvements in QoL, symptoms and depression15,16. 
These trials however have been single centre and have been relatively small. There remains ongoing debate as to 
when and how palliative care should be introduced to cardiac patients. Further trials are ongoing17.
However, focusing exclusively on patients with heart failure excludes a wider group of people with advanced 
heart disease, including those with coronary disease and valvular heart disease that could also benefit from care 
1Cardiology, Edinburgh Heart Centre, Royal Infirmary of Edinburgh, Little France Crescent, Edinburgh, EH16 4SA, 
UK. 2Primary Palliative Care Research Group, Usher Institute for Population Health Sciences and Informatics, 
University of Edinburgh, Medical School, Teviot Place, Edinburgh, EH8 9AG, UK. 3Edinburgh Clinical Trials Unit, 
University of Edinburgh, Outpatients Building, Floor Two, Room D36, Western General Hospital, Crewe Road South, 
Edinburgh, EH4 2XU, UK. 4Cardiology Department, Glasgow Royal Infirmary, Castle Street, Glasgow, G4 0SF, UK. 
5Edinburgh Health Services Research Unit, Usher Institute for Population Health Sciences and Informatics, University 
of Edinburgh, Medical School, Teviot Place, Edinburgh, EH8 9AG, UK. Correspondence and requests for materials 
should be addressed to M.A.D. (email: Martin.Denvir@ed.ac.uk)
received: 11 January 2016
Accepted: 24 March 2016
Published: 19 April 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:24619 | DOI: 10.1038/srep24619
planning. The increased use of transcatheter aortic valve implantation for very elderly and often frail people has 
identified another group whose care planning can be challenging.
In this novel Phase 2 randomised controlled trial we aimed to assess the feasibility and acceptability 
(to patients and carers) of a Future Care Planning (FCP) intervention in patients with different forms of advanced 
heart disease. The intervention was a complex intervention, with the trial being designed in line with Medical 
Research Council guidance18 and informed by extensive consultation with patient groups and healthcare pro-
fessionals using a series of semi-structured interviews19. Qualitative aspects of the intervention and the views of 
patients, carers and general practitioners (GPs) were evaluated using interviews.
Results
Over a 12 month period between 1st October 2013 and 31st September 2014, 408 patients were screened, 137 
met eligibility criteria of which fifty were randomised to an early or delayed intervention. Reasons for not enroll-
ing eligible patients are outlined in Fig. 1. The characteristics of enrolled patients are summarised in Table 1. 
For comparison, similar data for the screened population is provided in supplementary Table 1. Study patients 
were elderly with increased care needs as defined by a high Charleson Comorbidity Index, low mean Karnofsky 
Performance Scale and more than 50% of the cohort was considered frail according to the Canadian Frailty Scale. 
There was a low attrition rate for a palliative care study in such a frail population.
Heart failure was the primary diagnosis in 68% (n = 34) of patients; 14% (n = 7) with preserved and 54% 
(n = 27) with reduced left ventricle ejection fraction. There were no patients with an internal cardiac defibrillator 
(ICD). The remaining patients had aortic stenosis (n = 5, 10%) and acute coronary syndrome (n = 11, 22%). 64% 
of patients had a nominated carer who participated in the study, 19 in the early group and 13 in the delayed group. 
Three patients withdrew from the study during the 24 week follow-up period; 2 due to worsening illness and/or 
admission to hospital (delayed group) and 1 patient withdrew their consent for personal reasons (early group). 
There were 7 deaths; 4 in the early group and 3 in the delayed group (Fig. 1).
Process outcomes linked to the Future Care Plan. Components of the Future Care Plan were achieved 
more frequently in the early intervention group compared to the delayed intervention group by 12 weeks after 
discharge (Fig. 2). More patients in the early intervention group had an anticipatory care plan for acute dete-
rioration, a nominated Power of Attorney, a record of CPR discussions, a record of preferred place of care and 
preferred place of death compared to the delayed group. More patients in the early group were added to the GP 
palliative care register and more had a care summary shared across primary, secondary and emergency care 
services by 12 weeks after discharge. These differences had reduced but were still present at 24 weeks following 
discharge (see supplementary Table 2).
Figure 1. Flow chart of patients screened, excluded and recruited. Patients over the age of 70 were routinely 
screened on cardiology and general medical wards using the GRACE and EFFECT scores; an estimated risk of 
death within 12 months of at least 20% was the threshold level for trial inclusion the reasons for failing to recruit 
eligible patients are also listed in the flow chart.
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Patient outcomes - symptoms, QoL and anxiety/distress. The early and delayed treatment groups 
showed no differences in health related QoL at baseline (EQ5D index (mean(standard deviation)- early: 0.62 
(0.27) vs delayed: 0.60 (0.24)) and no significant adjusted mean difference at the 12 or 24 week time points 
(Table 2).
A similar pattern of results was seen for the EQ5D VAS, symptoms (both composite and individual symptom 
scores) measured using ESAS and no difference in anxiety/distress assessed using the Kessler Scale.
Healthcare outcomes. There was no difference in the number of unscheduled readmissions to hospital 
(Table 3) or unscheduled cardiovascular readmissions at 12 weeks or 6 months after discharge. Time to first read-
mission was also not significantly different between those who received the intervention in the first 12 weeks after 
discharge and those who had delayed intervention (hazard ratio 1.05, 95% confidence interval (CI) [0.34, 3.27]; 
p = 0.93). The duration of hospital stay, expressed as total days spent in hospital was reduced in the early interven-
tion group compared to the delayed group at 12 and 24 weeks after discharge. However, further analysis indicated 
that the reduced mean hospital stay in the early intervention group was attributable to a slight excess of deaths in 
that group. By 12 weeks there were 3 deaths in the early group and none in the delayed group. By 24 weeks there 
was one further death in the early group and 3 in the delayed group (Fig. 1). With regard to place of death, more 
patients in the early intervention group died in hospital (3 patients) compared to the delayed group (1 patient), 
while 1 patient in the early group died at home and none in the delayed group (Table 3). These numbers are small, 
Early (n = 25) Delayed (n = 25)
Age in years, Mean (SD) 81.9 (7.1) 80.2 (10.0)
Gender, Male (n, %) 17 (68.0) 13 (52.0)
Smoking Status (n, %)
 Never 15 (60.0) 10 (40.0)
 Previous 8 (32.0) 14 (56.0)
 Current 1 (4.0) 0 (0.0)
Formal Carer (n, %) 4 (16.0) 4 (16.0)
Informal Carer in Trial (n, %)
 None 6 (24.0) 12 (48.0)
 Daughter/son 6 (24.0) 6 (24.0)
 Partner/Spouse 11 (44.0) 6 (24.0)
 Other Family 2 (8.0) 1 (4.0)
Primary Diagnosis (n, %)
 ACS 8 (32.0) 3 (12.0)
 Heart Failure 14 (56.0) 20 (80.0)
 Valvular Disease 3 (12.0) 2 (8.0)
Comorbidities (n, %)
 CPD 6 (24.0) 8 (32.0)
 CVD 5 (20.0) 2 (8.0)
 Cancer 5 (20.0) 4 (16.0)
 CKD 13 (52.0) 18 (72.0)
 Dementia 0 (0.0) 1 (4.0)
 Diabetes 9 (36.0) 10 (40.0)
 Liver Disease 0 (0.0) 1 (4.0)
Routine Bloods, (Mean (SD))
 Creatinine (umol/l) 134.5 (65.0) 186.9 (120.4)
 Hemoglobin (g/l) 119.9 (20.7) 115.4 (19.2)
 Sodium (mmol/l) 136.5 (5.0) 137.0 (6.7)
 Urea (mmol/l) 12.3 (7.0) 17.1 (8.6)
 eGFR (mls/min) 50.1 (22.6) 34.5 (18.6)
Moderate or Severe LVSD (n, %) 16 (64.0) 14 (56.0)
Co-morbidity score
 Karnofsky Score (Mean (SD)) 62.8 (13.1) 61.6 (11.8)
  Charlson Comorbidity Index 
(Mean (SD)) 3.9 (1.8) 4.5 (1.5)
 Frail (%) 13 (52.0) 15 (60.0)
Table 1.  Baseline Patient Characteristics. Abbreviations: SD, standard deviation; N, number of observations; 
CKD, chronic kidney disease; CPD, chronic pulmonary disease; CVD, cerebrovascular disease; ACS, acute 
coronary syndrome; EF, ejection fraction; eGFR, estimated glomerular filtration rate; LVSD, left ventricular 
systolic dysfunction.
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as expected in this phase II trial, and statistical analysis does not indicate a difference. The overall death rate was 
comparable to that predicted by the prognostic scoring tools used at time of recruitment.
Carer outcomes. 19 carers from the early intervention group and 13 from the delayed intervention group 
contributed to questionnaire data on QoL, anxiety/distress and caregiver burden at 5 time points during the trial. 
At the key analysis time point of 12 weeks, where the early group had received the intervention and the delayed 
group had not, there was no difference in mean QoL score, anxiety/distress score and caregiver burden between 
the intervention groups (Table 4).
Qualitative findings. Key findings from interviews with patients, family members and GPs are presented 
in Appendix 1. Patients appreciated the ongoing contact and communication. Carers expressed a very positive 
experience mainly arising from the openness generated by the detailed future planning on a number of difficult 
issues. General practitioners also welcomed the initiation of end of life discussions by the hospital based cardi-
ology team.
Figure 2. Change in Process Outcomes during the intervention for early and delayed groups. Proportion 
(%) of patients in early and delayed arms of the trial with completion of each of the process measures included 
in the intervention which were discussed and documented in the written Future Care Plan at baseline, 12 and 24 
weeks after discharge.
Early (n = 25) Delayed (n = 25) Adjusted Mean
N Mean (SD) N Mean (SD) Difference (95%CI) P-Value
12 Weeks
 EQ5D Index 21 0.54 (0.29) 23 0.56 (0.24) − 0.01 (− 0.16,0.13) 0.86
 EQ5D VAS 19 60.9 (21.2) 22 57.0 (19.7) 4.75 (− 5.86,15.37) 0.37
 Edmonton Symptom Scale 19 24.5 (12.5) 23 23.5 (14.7) 0.62 (− 8.34,9.58) 0.89
 Kessler Distress Scale 17 16.7 (7.0) 22 16.8 (7.3) 0.17 (− 4.13,4.46) 0.94
24 Weeks
 EQ5D Index 20 0.45 (0.31) 20 0.55 (0.23) − 0.07 (− 0.25,0.11) 0.44
 EQ5D VAS 17 64.6 (19.1) 20 67.3 (16.3) − 0.42 (− 12.7,11.89) 0.95
 Edmonton Symptom Scale 17 21.8 (16.1) 20 18.8 (12.5) 3.18 (− 6.90,13.26) 0.52
 Kessler Distress Scale 17 16.5 (6.2) 17 13.6 (2.0) 2.70 (− 0.73,6.12) 0.12
Table 2.  Patient Questionnaire Outcomes. Note. Mean difference for early minus delayed intervention 
adjusted for baseline values. Abbreviations: N, number of observation; SD, standard deviation; CI, confidence 
interval; VAS, visual analogue scale.
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Discussion
This Phase 2, randomised controlled trial was completed successfully and provides valuable data to inform the 
design of a phase 3 trial. The findings have highlighted a need and have tested a design for an adequately powered 
trial in this area. In general patients and their carers were supportive, willing and enthusiastic to participate. In 
the early stages of the study, some patients were excluded by their own cardiologist due to concerns about having 
open conversations about death and dying. However, there was a progressive change in attitude such that towards 
the end of the recruitment phase the research team started to receive active referrals from consultant cardiolo-
gists. While this change could reflect a number of complex issues, it is likely to reflect improvements in under-
standing, acceptance and trust between the clinical and research teams as the trial progressed.
An important issue addressed in this feasibility study relates to recruitment and retention of patients. By 
focusing the screening process on elderly patients (>70 years) with acute cardiac conditions, we were able to 
identify a large number of eligible patients in a relatively short time period (12 months). Since only one patient 
chose to actively withdraw from the study, despite discussing many challenging life and death issues, we can 
conclude that patients and their families found discussions with well trained professionals to be helpful and 
Early 
(n = 25)
Delayed 
(n = 25) Risk Ratio
PMean (SD) Mean (SD) (95% CI)
12 Weeks
 All Unscheduled Admissions 0.5 (0.9) 0.4 (0.6) 1.25 (0.54,2.89) 0.6
 Cardiovascular Unscheduled Admissions 0.3 (0.7) 0.2 (0.5) 1.22 (0.41,3.62) 0.73
 Nights in Hospital 2.7 (5.5) 5.4 (9.4) 0.50 (0.37,0.67) < 0.01
6 Months
 All Unscheduled Admissions 0.8 (1.3) 0.7 (0.7) 1.23 (0.64,2.34) 0.54
 Cardiovascular Unscheduled Admissions 0.3 (0.8) 0.4 (0.6) 0.83 (0.33,2.11) 0.7
 Nights in Hospital 8.6 (15.3) 11.8 (17.1) 0.73 (0.61,0.88) < 0.01
Mortality (n(%)) Hazard Ratio (95% CI)
 12 weeks 3 (12.0) 0 (0.0) N/A N/A
 24 weeks 4 (16.0) 3 (12.0) 1.41 (0.32,6.30) 0.65
First Hospital Re-Admission (n(%))
 Within 12 weeks 6 (24.0) 7 (28.0) 1.05 (0.34,3.27) 0.93
 Within 6 months 13 (52.0) 14 (56.0) 0.94 (0.44,2.04) 0.89
Actual Place of Death (n(%))
 Hospital 3 (75) 1 (33.3) – –
 Hospice 0 (0.0) 1 (33.3) – –
 Care Home 0 (0.0) 1 (33.3) – –
 Home 1 (25) 0 (0.0) – –
Table 3.  Healthcare outcomes. Note. Hazard Ratio not applicable (N/A) due to zero events in the delayed 
intervention groups at 12 weeks. Place of death was analysed using descriptive statistics only. Abbreviations: N, 
number; SD, standard deviation; CI, confidence interval.
Early (n = 19) Delayed (n = 13) Adjusted Mean Difference
N Mean (SD) N Mean (SD) (95% CI) P
12 Weeks
 EQ5D Index 14 0.82 (0.13) 9 0.80 (0.20) − 0.05 (− 0.16,0.06) 0.38
 EQ5D VAS 15 83.5 (12.3) 10 81.8 (15.9) − 3.08 (− 11.7,5.50) 0.46
  Carer-giver Burden 
(Zarit 6) 15 5.9 (6.2) 9 5.2 (6.3) 0.84 (− 2.53,4.21) 0.61
 Kessler Distress Scale 15 14.3 (3.9) 10 15.8 (7.7) − 0.79 (− 3.55,1.97) 0.56
24 Weeks
 EQ5D Index 12 0.80 (0.13) 10 0.82 (0.18) − 0.06 (− 0.20,0.07) 0.32
 EQ5D VAS 12 79.6 (14.9) 10 83.1 (17.1) − 5.81 (− 15.7,4.03) 0.23
  Carer-giver Burden 
(Zarit 6) 11 6.5 (6.4) 10 4.8 (6.3) 1.70 (− 1.43,4.83) 0.27
 Kessler Distress Scale 11 15.3 (3.5) 10 16.1 (10.8) − 1.68 (− 4.47,1.11) 0.22
Table 4.  Carer Questionnaire Outcomes. Note. Mean difference for early minus delayed intervention adjusted 
for baseline values. Abbreviations: N, number of observations; SD, standard deviation; VAS, visual analogue 
scale.
www.nature.com/scientificreports/
6Scientific RepoRts | 6:24619 | DOI: 10.1038/srep24619
supportive. The questionnaire data confirmed this as there was no increase in anxiety/distress scores throughout 
the study among patients or carers. Indeed, it could be the case that the FCP intervention prevented increased 
distress over time. There was no significant impact of timing of the FCP intervention (early versus delayed) on 
trial outcomes. There was a slight effect of timing of the intervention on retention of patients, in the delayed group 
two withdrew due to progressive illness before the FCP intervention was delivered. These two patients effectively 
switched to “open- label” palliative care. This is not an unexpected finding in a randomised controlled trial of care 
planning in advanced heart disease and its impact in a larger trial will need to be carefully considered with respect 
to design and sample size.
This study has also supported the methodology of recruiting patients at the time of hospital discharge follow-
ing an unscheduled hospital admission. This is a key opportunity to begin discussions with patients and their 
families about issues that might otherwise be difficult to address, including cardiopulmonary resuscitation and 
its benefits and harms.
We included a broad range of people with cardiac conditions (acute coronary syndrome, valvular heart disease 
and all forms of heart failure) in the trial, many with co-morbidities. This is both equitable and important as we 
clearly identified a population at high risk of readmission and death over the 6 months following index admission. 
The high mortality risk applies to heart failure with reduced ejection fraction, normal ejection fraction and in 
people with predominantly valvular heart disease. High mortality risk is also present in patients with acute cor-
onary syndrome particularly accompanied by transient or persistent features of heart failure. These patients are 
well recognised to be at high risk of future clinical events20,21. However, unlike the HF patients most of the ACS 
patients were free of long term symptoms prior to admission. While this could have affected patient perspective 
with regard to Future Care Planning, qualitative interviews suggested that both ACS and HF patients were equally 
receptive to discussions regarding end of life issues.
Creation of a written Future Care Plan, agreed with the patient and their family, and shared electronically 
with the patient and other healthcare organisations was also a key component of the trial. Used in this way a 
FCP can support person-centred decision making about treatment and care options in community and hospital 
settings and represents a robust shared decision-making process involving patients and carers. Discussing and 
formulating the FCP took time and this can be difficult to manage in average clinical circumstances. The series 
of three separate 1 hour-long meetings spanning a 12 week period that continued while the patient was at home 
were important for this process. The challenges of adopting FCP processes in routine clinical practice need to be 
pragmatic and carefully considered as we move forward to a larger trial.
Use of generic questionnaires such the ESAS, EQ5D, EQ5D-VAS, Kessler was not burdensome for patients 
and the response rates were surprisingly high. However, the data generated in this small cohort was not sensitive 
or specific enough to observe a positive effect of the intervention. These issues and the relatively high mortality 
during follow-up limit the utility of this type of data as a trial endpoint. The use of heart failure specific QoL 
questionnaires may have detected more subtle changes22 or possibly a questionnaire designed to detect changes 
in symptoms and concerns towards the end of life23.
Re-admission to hospital and bed-utilisation represent important outcomes which merit consideration for a 
future trial. Hospitalisation is well known to impact on QoL and any reduction generated by a holistic care inter-
vention should, by inference, lead to improved QoL. Although the mean number of nights spent in hospital was 
lower in the early intervention group further analysis and correction for the small difference in mortality between 
groups showed that the number of days spent alive and out-of-hospital was not different between the two arms 
of the study.
A number of previous studies have used a holistic care intervention in patients with heart failure14–16. However, 
this study differs in several important ways. Firstly, we targeted patients with a range of heart conditions, includ-
ing heart failure. Secondly, we used a risk-threshold based on prognostic scoring tools to select patients for the 
study. These scoring tools are recognised to be highly predictive in cohorts of patients but less predictive for indi-
vidual patients24. However, our aim was not to make an accurate prognostic judgment about life expectancy for 
an individual patient but rather to identify a population of patients at high risk of death or deterioration in their 
health and who may therefore benefit from additional holistic care. Our trial has shown quite clearly that these 
prognostic tools can provide basis for selecting high risk patients with a high burden of comorbidity as illustrated 
by the high Charlson, frailty and Karnofsky scores observed in those recruited.
Finally, we created and shared a Future Care Plan between hospital, GP and the emergency care services using 
an electronic record called the Key Information Summary (KIS). This is a fundamental component of any inter-
vention which aims to alter the experience of the patient and their use of healthcare services in the final phase of 
an advanced illness. It is an approach which has been much called for by a number of researchers in this field25,26.
This novel phase 2 trial has confirmed that a randomised trial approach using FCP is feasible and acceptable 
to patients with a range of heart disease conditions associated with high risk of death. The intervention clearly 
improved the documentation of a number of key issues linked to patient-centred healthcare. It has defined com-
ponents necessary for a larger, adequately powered clinical trial with the potential to influence end of life care for 
people with advanced heart disease.
Methods
The study protocol was approved by the Lothian Research Ethics Committee (reference 12/SS/0223) and con-
ducted in collaboration with a UKCRC-registered Clinical Trials Unit. Patients were recruited, consented and 
randomised by the trial nurse according to the approved protocol and in accordance with Good Clinical Practice 
guidelines. Recruitment was undertaken in cardiology, medical and care of the elderly hospital wards following 
an unscheduled hospital admission with heart failure and or acute coronary syndrome based on European Society 
of Cardiology guidelines1,27. Eligibility criteria included a predicted 12 month mortality risk of 20% or greater 
estimated using the Global Registry of Acute Coronary Syndrome (GRACE) score for ACS28 and the Enhanced 
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Feedback for Effective Cardiac Treatment (EFFECT) score for heart failure and patients with aortic stenosis who 
presented with heart failure29. Exclusion criteria included moderate/severe dementia, prognosis less than 30 days 
and those already on a palliative care register. Enrolled patients were asked to identify an informal carer to take 
part in the study. Patients and carers gave written informed consent and knew they could withdraw from the 
study at any time. Patients were randomised using a crossover design in a 1:1 ratio using random permuted blocks 
to receive one of two care pathways: pathway 1 included 12 weeks of a Future Care Plan intervention (FCP) at 
discharge followed by crossover to 12 weeks of usual care (early group) or pathway 2 which included 12 weeks of 
usual care followed by cross over to 12 weeks of FCP (delayed group). This design was ethical in that it ensured 
that all patients received the FCP intervention and also allowed us to assess potential impact of the timing of the 
intervention on process and outcomes.
Questionnaires were completed at 5 time points by patients and carers - baseline (at discharge), 6, 12, 18 and 
24 weeks after discharge in the home setting. Response rates were high with 95% of surviving patients and 80% of 
carers providing responses at each of the 5 time points.
FCP Intervention. The intervention lasted 12 weeks and had three main components:
1. An initial, one hour semi-structured meeting with the trial cardiologist (MD) and the trial nurse specialists 
involving the patient and their carer; followed by two 1 hour meetings with the trial nurse in the patient’s 
home at 6 and 12 weeks.
2. Discussion and documentation of an agreed personal Future Care Plan which was sent to each pa-
tient and uploaded by the general practitioner using the electronic KIS (used in Scotland to routinely 
communicate with out- of-hours and hospital services http://www.snughealth.org.uk/gp-software/
key-information-summary).
3. Ongoing telephone support (available Monday to Friday, 9am–5pm) from the trial nurse for the 12 weeks 
offering advice, support and information about their healthcare and social needs.
In preparation for the study, the cardiologist and the trial nurse specialist attended an advanced communica-
tion workshop that included experiential training FCP. They also had short clinical attachments with community 
palliative care teams involving FCP.
The first interview/meeting focused on the information needs, key concerns and priorities of the patient and 
carer using a semi-structured interview guide to provide a consistent framework. The key topics discussed were: 
exploring their experiences of being in hospital, what treatments had been given or changed, their understanding 
and expectations about their condition, nominating a Power of Attorney or a surrogate decision maker, prefer-
ences for place of care should they deteriorate in the future (including place of care when dying) and likely out-
comes of treatment; specifically discontinuing life-prolonging treatments and cardiopulmonary resuscitation. The 
final FCP document also included a detailed anticipatory care plan describing actions to be taken if the patient’s 
health deteriorated acutely. A paper copy of the FCP was posted to the patient after this first meeting and sent 
to the GP. The trial team also recommended to the GP that the patient was added to the practice palliative care 
register. At the 6 week meeting, the patient’s condition and their views and perceptions about their health and 
care needs were explored once again by the trial nurse. Any concerns or needs not raised during the first meeting 
were discussed. The patient’s FCP was reviewed with them and their carer and any changes agreed and noted. The 
updated version of the FCP was again sent back to the patient and to their GP practice for upload into the KIS. 
The 12 week meeting focused on plans for handing care coordination over to the primary care team and ongoing 
use of the FCP as part of this. In all cases, the trial nurse phoned the GP practice to try and speak with the patient’s 
GP to ensure that information about the patient’s current and Future Care Plans were communicated effectively. A 
final version of the FCP was sent to the GP for upload to the KIS. Completed Do Not Attempt Cardiopulmonary 
Resuscitation (DNACPR) forms were held by the patient and a special note added to the KIS.
Outcome measures. Patients completed QoL questionnaires (EQ5D)30 before discharge and at 6, 12, 18 
and 24 weeks. EQ-5D dimension scores were converted to index scores using UK population values31. They 
also completed a symptom scoring tool (Edmonton Symptom Assessment Scale (ESAS)32 and a stress/anxiety 
questionnaire (Kessler)33 at these same time points. Carers were asked to complete the EQ-5D, EQ5D-Visual ana-
logue scale (Health-thermometer), Kessler Distress Score and the ZARIT634, assessing caregiver burden, at each 
time point. All scheduled and unscheduled hospital admissions and all-cause and disease specific mortality were 
obtained from electronic health records over the 6 month period following recruitment. The primary outcome 
variable was health related QoL (EQ5D index) measured at the 12 week time point.
A range of other clinical and demographic data was collected from the patient’s care record including data 
required to complete the Charleson Comorbidity Index35, the Canadian Study of Health and Ageing Clinical 
Frailty Scale36 and the Karnofsky Performance Scale37.
Qualitative interviews were undertaken as part of the post-trial evaluation to assess the views of patients 
(n = 12), carers (n = 8) and general practitioners (GPs, n = 6) about the trial. Patients were selected randomly 
with a similar number in the early and delayed groups. All interviews were digitally recorded, transcribed ver-
batim and analysed thematically with the assistance of computer software (Nvivo) designed for this purpose38.
Statistical analysis. The study sample size was chosen as a pragmatic number that would allow us to explore 
recruitment and retention of patients, a range of outcomes and the feasibility of a randomised trial approach. 
The primary outcome was mean quality of life (EQ5D-index) at 12 weeks comparing patients receiving early 
and delayed intervention. This was assessed using analysis of covariance (ANCOVA) adjusting for the base-
line EQ5D-index. The intervention effect is presented as the adjusted mean difference (for early minus delayed 
www.nature.com/scientificreports/
8Scientific RepoRts | 6:24619 | DOI: 10.1038/srep24619
intervention), its 95% confidence interval (CI) and the p-value associated with the test of the null hypothesis 
that the adjusted mean difference equals zero. Secondary patient-outcomes included EQ5D-index at 24 weeks, 
EQ5D-VAS, symptom score and anxiety/distress at 12 and 24 weeks. Carer-outcomes formed part of an explor-
atory analysis. Secondary patient-outcomes and carer outcomes were analysed for continuous outcomes using 
the same method as the primary outcome using ANCOVA and adjusting for the baseline measurement. Time to 
event patient-outcomes were analysed using the Cox proportional hazards model and reported using a hazard 
ratio and 95% CI. Outcomes representing count data were analysed by Poisson regression and reported using risk 
ratio and 95% CI. Outcomes representing binary data were analysed by logistic regression and reported as odds 
ratio and 95% CI.
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